Example: Heart Attack

Search clinical trials for: Arsenic trioxide

Total 131 results

NCT04336644

Not yet recruiting

Continuous Versus Intermittent cARdiac Electrical moNitorinG

Conditions: Torsades de Pointe Caused by Drug; Long QT Syndrome
NCT04175587

Not yet recruiting

Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL

Conditions: Acute Promyelocytic Leukaemia
NCT03980665

Recruiting

The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART

Conditions: HIV/AIDS
NCT03855371

Recruiting

Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS

Conditions: P53 Mutation; Myeloid Malignancy; MDS; Aml
NCT03751917

Not yet recruiting

Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia

Conditions: Acute Promyelocytic Leukemia
NCT03624270

Recruiting

Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia

Conditions: Acute Promyelocytic Leukemia
NCT03503864

Recruiting

Clinical Trial of Arsenic Trioxide Combined Chemotherapy in the Treatment of Stage 4 Neuroblastoma

Conditions: Neuroblastoma
NCT03381781

Not yet recruiting

Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations

Conditions: Acute Myeloid Leukemia; P53 Mutation
NCT03377725

Not yet recruiting

Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS)

Conditions: Myelodysplastic Syndromes; P53 Mutation
NCT03318016

Recruiting

Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia; Relapsed/Refractory Acute Myeloid Leukemia
NCT03096496

Unknown status

Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy

Conditions: Acute Promyelocytic Leukemia
NCT03048344

Completed

A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders

Conditions: Advanced Hematological Disorders
NCT03031249

Recruiting

Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia

Conditions: AML
NCT02966301

Active, not recruiting

Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide

Conditions: Chronic Graft-Versus-Host Disease; Immune System Diseases
NCT02956772

Not yet recruiting

Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients

Conditions: Primary Hepatocellular Carcinoma
NCT02899169

Recruiting

Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)

Conditions: Acute Promyelocytic Leukemia
NCT02788201

Completed

Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

Conditions: Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms
NCT02757040

Unknown status

Combination of Ibrutinib and As2O3 in the Treatment of CLL

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
NCT02699723

Not yet recruiting

Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer

Conditions: Skin Basal Cell Carcinoma
NCT02688140

Recruiting

Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia

Conditions: Acute Promyelocytic Leukemia
NCT02551718

Recruiting

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

Conditions: Acute Leukemia of Ambiguous Lineage; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myeloid Leukemia
NCT02339740

Active, not recruiting

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

Conditions: Acute Promyelocytic Leukemia With PML-RARA
NCT02312037

No longer available

Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy

Conditions: CD33 Positive Acute Myelogenous Leukemia
NCT02200978

Enrolling by invitation

A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia

Conditions: Childhood Acute Promyelocytic Leukemia
NCT02190695

Active, not recruiting

Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia
NCT02133287

Active, not recruiting

To Evaluate The Safety and Efficacy of 'AVI' Stent Comparing With Firebird2® For Treating Coronary Revascularization

Conditions: Ischemic Heart Disease; Myocardial Ischemia; Coronary Disease; Acute Coronary Syndrome
NCT02117843

Recruiting

The Safety and Efficacy of 'AVI' Stent for Treating Coronary Revascularization

Conditions: Ischemic Heart Disease; Myocardial Ischemia; Coronary Disease; Acute Coronary Syndrome
NCT02066870

Unknown status

Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI

Conditions: Non-small Cell Lung Cancer
NCT02018757

Unknown status

Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC

Conditions: Carcinoma, Hepatocellular
NCT01987297

Active, not recruiting

Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL

Conditions: Acute Promyelocytic Leukemia
NCT01950611

Unknown status

Proteasome Inhibition in Acute Promyelocytic Leukemia

Conditions: Relapsed Acute Promyelocytic Leukemia
NCT01861912

Unknown status

Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma

Conditions: Carcinoma, Hepatocellular
NCT01835288

Withdrawn

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Conditions: Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Acute Myeloid Leukemia
NCT01791894

Completed

Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma

Conditions: Basal Cell Carcinoma of the Skin; Recurrent Skin Cancer
NCT01738360

Terminated

Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC)

Conditions: Systemic Lupus
NCT01470248

Completed

Study of Arsenic Trioxide in Small Cell Lung Cancer

Conditions: Lung Cancer; Cancer of Lung; Pulmonary Cancer; Pulmonary Neoplasms; Carcinoma, Small Cell
NCT01428128

Completed

Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector

Conditions: Cancer Other Than Leukemia
NCT01409161

Recruiting

Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

Conditions: Acute Promyelocytic Leukemia With PML-RARA
NCT01404949

Active, not recruiting

Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy

Conditions: Acute Promyelocytic Leukemia
NCT01397734

Terminated

Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)

Conditions: Chronic Myelogenous Leukemia
NCT01191541

Unknown status

Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)

Conditions: Leukemia
NCT01184053

Terminated

Trisenox® in Women With Metastatic Endometrial Cancer

Conditions: Endometrial Carcinoma
NCT01014546

Terminated

Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis

Conditions: Essential Thrombocythemia; Polycythemia Vera; Primary Myelofibrosis
NCT00985530

Terminated

Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia

Conditions: Acute Promyelocytic Leukemia
NCT00899015

Completed

Assessing Arsenic Trioxide in Young Patients With Leukemia or Lymphoma Who Were Treated on Clinical Trial NCI-00-C-0070J

Conditions: Leukemia; Lymphoma
NCT00866918

Unknown status

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

Conditions: Childhood Acute Promyelocytic Leukemia (M3); Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
NCT00850304

Completed

Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide

Conditions: Leukemia, Myeloid, Acute
NCT00803530

Terminated

Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndromes

Conditions: Myelodysplastic Syndromes
NCT00720564

Completed

Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma

Conditions: Brain and Central Nervous System Tumors
NCT00675870

Unknown status

Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia

Conditions: Acute Promyelocytic Leukemia